16 research outputs found
Evaluation a renal function of patients with Medication-overuse headache (MOH)
Excessive drug use causes Medication-overuse headache (MOH) which can be manifested of chronic daily headaches, occurring monthly 15 or more days, when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug-induced disorders suggest that increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MOH),were treated with NSAIDs in combination with other drugs (analgesics, triptans and antidepressants) and compared patients treated only with Diclofenac, Piroxicam, Ketoprofen, Paracetamol, Ibuprofen and Celecoxib, Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum). Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria and Ξ²2-microglobulin will be used. Significant glomerular and tubular damage has been reported, and patients on combination therapy with NSAIDs and other drugs (analgesics, triptans, and antidepressants) have seen more glomerular changes than patients treated with NSAID monotherapy.
Keywords: Medication-overuse headache, Nephrotoxicity, Nonsteroidalantiinflammatory drugs
Migraine and the effects of NSAIDS on renal function
Trigeminovascular system (TGV) activation is a basic mechanism for generating pain during a migraine attack. Many experimental results highlight the importance of the cyclooxygenase system in the peripheral arm of TGV and suggest that NSAIDs may be effective in migraine therapy through the action of these peripheral nociceptors. Inhibition of NSAID-mediated prostaglandin synthesis prevents neurogenically mediated inflammation of the trigeminal system and reduces pain, but at the same time
inhibition of prostaglandin in the kidney may reduce renal blood flow,speed glomerular filtration retention. and water. The purpose of the study is to follow the renal function, in patients with cefaleamigraine that has been treated for a long period, treated with Diclofenac and Paracetamol.We used Jaffeβs method for the determination of serum/urine creatinine and Π΅nzymatic assays for urea and uric acid in serum and ᡧ glutamyl transferase (ᡧ-GT) in serum and jon selective electrode (ISE) are used for determination of electrolite in serum. We used nephelometry by Ξ²2 microglobulin (Ξ²2M) and photoelectric colorimetry for microalbuminuria in urine, to monitor glomerular and tubular functioning. Any history of kidney diseases was exclusion criteria to enter the study. In chronic treatment of patients with headache with Diclofenac and Paracetamol in symptomatic headaches, they have been confirmed as renoprotective in their use.
Keywords: non-steroidal anti-inflammatory drugs, migraine, renal function, trigeminovascular syste
medication-overuse headache (MOH)
Migraine is a common headache disorder that causes significant disabilities. Headache developed or significantly worsened during medication overuse (for simple analgesics and combination acute medications, intake must be 15 days or more per month for triptans, ergotamines, opioids, and combination analgesics; 10 days per month sufficient to get a diagnosis of Medication-overuse headache-MOH). A recent epidemiologic study on drug-induced disorders demonstrated that excessive drug use can lead to nephrotoxicity. Microalbuminuria was common in patients under the influence of nephrotoxic drugs. Subclinical renal damage cannot be identified by routine tests (serum creatinine), and microalbuminuria is a more sensitive indicator of renal dysfunction. The aim is to confirm the sensitivity of certain biomarkers when comparing patients treated with NSAIDs in combination with other drugs (analgesics, triptans and antidepressants) with patients treated with monotherapy by NSAIDs Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods), enzymatic assay for urea serum and Jon selective electrode (ISE) are used fordetermination of electrolite in serum. Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria and Ξ²2-
microglobulin will be used. In the case of combination therapy (analgesics, triptans and antidepressants) a significant effect on the increase of microalbuminuria has been demonstrated.
Keywords: Medication-overuse headache, Nephrotoxicity, Microalbuminuria
Comparison of the sensitivity of several biomarkers in patients with medication overuse headache (MOH)
Migraine is a common headache disorder that causes significant disabilities. Headache developed or significantly worsened during medication overuse (for simple analgesics and combination acute medications, intake must be 15 days or more per month for triptans, ergotamines, opioids, and combination analgesics; 10 days per month sufficient to get a diagnosis of Medication-overuse headache-MOH). A recent epidemiologic study on drug-induced disorders demonstrated that excessive drug use can lead to nephrotoxicity. Microalbuminuria was common in patients under the influence of nephrotoxic drugs. Subclinical renal damage cannot be identified by routine tests (serum creatinine), and microalbuminuria is a more sensitive indicator of renal dysfunction. The aim is to confirm the sensitivity of certain biomarkers when comparing patients treated with NSAIDs in combination with other drugs (analgesics, triptans and antidepressants) with patients treated with monotherapy by NSAIDs Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods), enzymatic assay for urea serum and Jon selective electrode (ISE) are used for determination of electrolyte in serum. Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria and Ξ²2-microglobulin will be used. In the case of combined therapy with NSAIDs and other medications (analgesics, triptans and antidepressants), a significant effect on the increase of
microalbuminuria has been demonstrated, which signals us for a more sensitive indicator in compared to Ξ²2M which as
specific bioindicator did not show a measured sensitivity for the detection of early changes in the tubular level. Significant glomerular damage has been reported in patients with combination therapy than patients treated with NSAID monotherapy. Following the levels of specific biomarkers, we can use them as signals for early detection of nephrotoxicity, especially in patients treated with combination therapy requiring special attention when administering them
Evaluation a renal function of patients with Medication- overuse headache (MOH)
Excessive drug use causes Medication-overuse headache (MOH) which can be manifested with chronic daily headaches, occurring monthly 15 or more days when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug- induced disorders suggest that an increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MOH), who were treated with NSAIDs in combination with other drugs (analgesics, triptans, and antidepressants) and compared patients treated only with Diclofenac, Piroxicam, Ketoprofen, Paracetamol, Ibuprofen, and Celecoxib. Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum). Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria, and Ξ²2-microglobulin will be used. Significant glomerular and tubular damage has been reported, and patients on combination therapy with NSAIDs and other drugs (analgesics, triptans, and antidepressants) have seen more glomerular changes than patients treated with NSAID monotherapy
Nefrotoxicity of NSAID
Headache is one of the most common symptoms encountered in the general population as well as in medical practice worldwide. Migraine is the most frequent cause of headache and a common disabling neurological disorder with a serious socio-economical burden. Despite the introduction more than a decade ago of a new class of migraine-specific drugs with superior efficacy, the triptans, NSAIDs remain the most commonly used therapies for the migraine attack. Some are available over the counter and likely to be abused.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are capable of inducing a variety of renal function abnormalities. The adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) are mediated via inhibition of prostaglandin synthesis by non-specific blocking cycloxygenase, leading to vasoconstriction and reversible mild renal impairment in hypoperfusion. When unopposed, this may lead to acute kidney injury (AKI). Although this presents as AKI, chronic use of NSAIDs may result in chronic kidney disease (CKD). The standard metrics to follow the progression of AKI, like serum creatinine and blood urea levels, are inconvenient and depend on kidney injury. Thatβs why we must use specific markers for early detection. In the present review,we will follow the levels of specific urinar biomarkers which we can use as signals for early detection of nephrotoxicity. There has not been prespective study for nefrotoxicity of NSAID used in long term by a pacient with chronic pain
ΠΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ Π½Π° ΡΠ΅Π½Π°Π»Π½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ° ΠΊΠ°Ρ Ρ ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ
ΠΠ»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠ°ΡΠ° Π΅ Π΅Π΄Π΅Π½ ΠΎΠ΄ Π½Π°ΡΡΠ΅ΡΡΠΈΡΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈ ΡΡΠΎ ΡΠ΅ ΡΡΠ΅ΡΠ°Π²Π° ΠΊΠ°Ρ ΠΎΠΏΡΡΠ°ΡΠ° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡΠ°, ΠΊΠ°ΠΊΠΎ ΠΈ Π²ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°ΡΠ° ΠΏΡΠ°ΠΊΡΠ° Π²ΠΎ ΡΠ΅Π»ΠΈΠΎΡ ΡΠ²Π΅Ρ. Π ΠΏΠΎΠΊΡΠ°Ρ Π²ΠΎΠ²Π΅Π΄ΡΠ²Π°ΡΠ΅ΡΠΎ Π½Π° Π½ΠΎΠ²Π° ΠΊΠ»Π°ΡΠ° Π½Π° ΠΌΠΈΠ³ΡΠ΅Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ ΡΠΎ ΡΡΠΏΠ΅ΡΠΈΠΎΡΠ½Π° Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ ΠΏΡΠ΅Π΄ ΠΏΠΎΠ²Π΅ΡΠ΅ ΠΎΠ΄ Π΅Π΄Π½Π° Π΄Π΅ΡΠ΅Π½ΠΈΡΠ°, ΡΡΠΈΠΏΡΠ°Π½ΠΈ, NSAIDs ΠΎΡΡΠ°Π½ΡΠ²Π°Π°Ρ Π½Π°ΡΡΠ΅ΡΡΠΎ ΠΊΠΎΡΠΈΡΡΠ΅Π½ΠΈΡΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π° Π½Π°ΠΏΠ°Π΄ Π½Π° ΠΌΠΈΠ³ΡΠ΅Π½Π°. ΠΡΡΠΎ ΡΠ°ΠΊΠ°, Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈΡΠ΅ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX (Piroxicam, Ketoprofen, Ibuprofen) ΡΠ΅ Π½Π°ΡΡΠ΅ΡΡΠΎ ΠΏΡΠΎΠΏΠΈΡΠ°Π½ΠΈΡΠ΅ β NSAIDs Π·Π° ΡΡΠ΅ΡΠΌΠ°Π½ Π½Π° Π³Π»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠΈ. Celecoxib Π΅ Π΄ΡΡΠ³ Π²ΠΈΠ΄ Π½Π° NSAID, ΠΊΠΎΡΠ° Π΅ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½Π° Π²ΠΎ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ Π½Π΅ΠΊΠΎΠ»ΠΊΡ Π³ΠΎΠ΄ΠΈΠ½ΠΈ, ΡΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΈ Π½Π° Π΄Π΅ΡΡΡΠ²ΡΠ²Π°ΡΠ΅. ΠΠ΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈΡΠ΅ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ (NSAID)s ΡΠ΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΈ Π΄Π° ΠΏΡΠ΅Π΄ΠΈΠ·Π²ΠΈΠΊΠ°Π°Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π½Π°ΡΡΡΡΠ²Π°ΡΠ° Π½Π° Π±ΡΠ±ΡΠ΅ΠΆΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ°. ΠΠΎΡΡΠ΅Π΄ΡΠ²Π°Π°Ρ ΠΏΡΠ΅ΠΊΡ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΈΡΠ° Π½Π° ΡΠΈΠ½ΡΠ΅Π·Π°ΡΠ° Π½Π° ΠΏΡΠΎΡΡΠ°Π³Π»Π°Π½Π΄ΠΈΠ½ ΡΠΎ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎ Π±Π»ΠΎΠΊΠΈΡΠ°ΡΠ΅ Π½Π° ΡΠΈΠΊΠ»ΠΎΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Π°, ΡΡΠΎ Π΄ΠΎΠ²Π΅Π΄ΡΠ²Π° Π΄ΠΎ Π²Π°Π·ΠΎΠΊΠΎΠ½ΡΡΡΠΈΠΊΡΠΈΡΠ° ΠΈ ΡΠ΅Π²Π΅ΡΠ·ΠΈΠ±ΠΈΠ»Π½ΠΎ Π±Π»Π°Π³ΠΎ Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅ ΠΏΡΠΈ Ρ
ΠΈΠΏΠΎΠΏΠ΅ΡΡΡΠ·ΠΈΡΠ°. ΠΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠ°Π½Π°ΡΠ° ΡΠ°Π½Π° Π΄Π΅ΡΠ΅ΠΊΡΠΈΡΠ° ΠΌΠΎΠΆΠ΅ Π΄Π° Π΄ΠΎΠ²Π΅Π΄Π΅ Π΄ΠΎ Π°ΠΊΡΡΠ½ΠΎ Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅ (AKI). Π‘ΡΠ°Π½Π΄Π°ΡΠ΄Π½ΠΈΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈ, ΠΊΠ°ΠΊΠΎ ΡΡΠΎ ΡΠ΅ ΡΠ΅ΡΡΠΌΡΠΊΠΈΡΠ΅ Π½ΠΈΠ²ΠΎΠ° Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ ΠΈ ΡΡΠ΅Π°, ΡΠ΅ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π·Π° ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡΠ°ΡΠ° Π½Π° AΠI ΠΈ Π·Π°Π²ΠΈΡΠ°Π°Ρ ΠΎΠ΄ ΡΡΠ΅ΠΏΠ΅Π½ΠΎΡ Π½Π° ΡΠ΅Π½Π°Π»Π½ΠΎΡΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅. ΠΠ°ΡΠΎΠ° Π΅ Π½Π΅ΠΎΠΏΡ
ΠΎΠ΄Π½ΠΎ Π΄Π° ΡΠ΅ ΠΊΠΎΡΠΈΡΡΠ°Ρ ΠΏΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΈ Π·Π° ΡΠ°Π½ΠΎ ΠΎΡΠΊΡΠΈΠ²Π°ΡΠ΅. Π¦Π΅Π»ΡΠ° Π½Π° ΡΡΡΠ΄ΠΈΡΠ°ΡΠ° Π΅ Π΄Π° ΡΠ΅ ΡΠ»Π΅Π΄ΠΈ Π±ΡΠ±ΡΠ΅ΠΆΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ° ΠΊΠ°Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΡΠ΅ΡΠΈΡΠ°ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅ΡΠ°Π»Π΅Π°-ΠΌΠΈΠ³ΡΠ΅Π½Π°.
ΠΠΏΠΈΡ Π½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΠ°ΡΠ° β ΠΠΎΡΠΈΡΡΠ΅Π½Π° Π΅ JaffΠ΅-ΠΎΠ²Π°ΡΠ° ΠΌΠ΅ΡΠΎΠ΄Π° Π·Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ²Π°ΡΠ΅ Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ Π²ΠΎ ΡΠ΅ΡΡΠΌ/ΡΡΠΈΠ½Π° ΠΈ Π΅Π½Π·ΠΈΠΌΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ Π·Π° ΡΡΠ΅Π° ΠΈ ΠΌΠΎΠΊΡΠ°ΡΠ½Π° ΠΊΠΈΡΠ΅Π»ΠΈΠ½Π° Π²ΠΎ ΡΠ΅ΡΡΠΌ ΠΈ ᡧ-glutamyl transferase (ᡧ-GT) Π²ΠΎ ΡΡΠΈΠ½Π° / ΡΠ΅ΡΡΠΌ. ΠΡΠ·ΠΈΠ½Π°ΡΠ° Π½Π° Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½Π°ΡΠ° ΡΠΈΠ»ΡΡΠ°ΡΠΈΡΠ° - Glomerular filtration rate (GFR) Π΅ ΠΏΡΠ΅ΡΠΌΠ΅ΡΠ°Π½Π° ΡΠΎ ΠΏΠΎΠΌΠΎΡ Π½Π° Cockcroft Gaunt ΡΠΎΡΠΌΡΠ»Π°ΡΠ° ΠΈ ΠΠΎΠ½-ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ Π΅Π»Π΅ΠΊΡΡΠΎΠ΄ΠΈ -(ISE) Π·Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ²Π°ΡΠ΅ Π½Π° Π΅Π»Π΅ΠΊΡΡΠΎΠ»ΠΈΡΠΈΡΠ΅ Π²ΠΎ ΡΠ΅ΡΡΠΌΠΎΡ. ΠΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ ΡΠ΅ ΠΊΠΎΡΠΈΡΡΠ΅Π½ΠΈ Π·Π° ΠΎΠ΄ΡΠ΅Π΄ΡΠ²Π°ΡΠ΅ Π½Π° N-Π°ΡΠ΅ΡΠΈΠ»βΞ²-D--Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ΄Π°Π·Π° (NAG) ΠΈ ΠΠ»Π°Π½ΠΈΠ½ Π°ΠΌΠΈΠ½ΠΎΠΏΠ΅ΠΏΡΠΈΠ΄Π°Π·Π° (AAP). ΠΠΌΡΠ½ΠΎΡΡΡΠ±ΠΎΠ΄ΠΈΠΌΠ΅ΡΡΠΈΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ, Π½Π΅ΡΠ΅Π»ΠΎΠΌΠ΅ΡΡΠΈΡΠ° ΠΈ ΡΠΎΡΠΎΠ΅Π»Π΅ΠΊΡΡΠΈΡΠ½a ΠΊΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ° ΡΠ΅ ΡΠΏΠΎΡΡΠ΅Π±Π΅Π½ΠΈ Π·Π° ΠΎΠ΄ΡΠ΅Π΄ΡΠ²Π°ΡΠ΅ Π½Π° ΡΡΠΈΠ½Π°ΡΠ½ΠΈΡΠ΅ Π°Π»Π±ΡΠΌΠΈΠ½ΠΈ, ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΠ°ΡΠ°, Ξ±1-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΡ (Ξ±1M) ΠΈ Ξ²2-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ (Ξ²2Π) Π·Π° Π΄Π° ΡΠ΅ ΡΠ»Π΅Π΄ΠΈ Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½Π°ΡΠ° ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ°. Π’Π΅ΡΡΠΈΡΠ°Π²ΠΌΠ΅ 136 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅ΡΠ°Π»Π΅Π° ΠΌΠΈΠ³ΡΠ΅Π½Π° ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ Π΄ΠΎΠ»Π³ΠΈ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈ Π½Π° 10, 5 ΠΈ 1 Π³ΠΎΠ΄ΠΈΠ½a ΡΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ NSAIDs Π·Π°ΡΠ½ΠΎΠ²Π°Π½ΠΈ Π½Π° ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΈΡΠ° Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ (Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ, Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ²Π½ΠΈ ΠΈ ΡΡΠΈΠΏΡΠ°Π½ΠΈ). ΠΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΠ΅ ΡΠΏΠΎΡΠ΅Π΄Π΅Π½ΠΈ ΡΠΎ 80 ΠΈΡΠΏΠΈΡΠ°Π½ΠΈΡΠΈ ΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° Π³ΡΡΠΏΠ° (ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π²ΠΎ ΠΎΠ΄Π½ΠΎΡ Π½Π° ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΡ), Π° Π½Π΅ΠΊΠΎΠΈ Π³ΡΡΠΏΠΈ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎ Π΅Π΄Π΅Π½ ΠΌΠ΅ΡΠ΅Ρ ΠΏΠ°ΡΠ·Π° Π±Π΅Π· Π½ΠΈΠΊΠ°ΠΊΠ²Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎ ΡΠ΅ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠ°Π½ΠΈ.
Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ: ΠΠΎΠ½ΡΡΠ°ΡΠΈΡΠ°Π½ΠΎ Π΅ Π΄Π΅ΠΊΠ° Π½Π΅ΠΌΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈ Π·Π½Π°ΡΠ°ΡΠ½ΠΈ ΠΏΡΠΎΠΌΠ΅Π½ΠΈ Π²ΠΎ Π²ΡΠ΅Π΄Π½ΠΎΡΡΠΈΡΠ΅ Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ΠΎΡ (ΡΡΠΈΠ½Π°/ΡΠ΅ΡΡΠΌ), ΡΡΠ΅Π°ΡΠ°, Π΅Π»Π΅ΠΊΡΡΠΎΠ»ΠΈΡΠΈΡΠ΅ Π²ΠΎ ΡΠ΅ΡΡΠΌΠΎΡ ΠΈ GFR. ΠΠΎ ΠΎΠ΄Π½ΠΎΡ Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ Π½Π° ΡΡΠΈΠ½Π°ΡΠ° (NAG, AAP, ᡧ-GT, ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΡΠ° ΠΈ Ξ± 1 M), ΡΡΠ²ΡΠ΄Π΅Π½ΠΈ ΡΠ΅ ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½ΠΈ Π·Π³ΠΎΠ»Π΅ΠΌΡΠ²Π°ΡΠ° Π½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡΠΈΡΠ΅ ΠΊΠ°Ρ ΡΠΈΡΠ΅ Π³ΡΡΠΏΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ NSAIDs ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Caffetin+NSAID Π²ΠΎ ΡΠΏΠΎΡΠ΅Π΄Π±Π° ΡΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° Π³ΡΡΠΏΠ° Π½Π° ΠΈΡΠΏΠΈΡΠ°Π½ΠΈΡΠΈ, Π° ΡΠΎΡΡΠΎΡΠ±Π°ΡΠ° ΡΠ΅ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΈΡΠ° ΠΏΠΎ ΠΏΠ°ΡΠ·Π° ΠΎΠ΄ Π΅Π΄Π΅Π½ ΠΌΠ΅ΡΠ΅Ρ Π±Π΅Π· Π½ΠΈΠΊΠ°ΠΊΠ²Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ°. ΠΡΠΈ ΡΡΠ΅ΡΠΌΠ°Π½ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° Π½Π° COX (Piroxicam, Ketoprofen, Ibuprofen), ΡΠ΅Π»Π°ΡΠΈΠ²Π½ΠΎ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ COX2 ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ (Nimesulid/Meloxicam) ΠΈ ΡΠΎ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX2 (Celecoxib) ΠΏΡΠΈ ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΠΎΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅Ρ (ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΠ°) Π΅ Π·Π°Π±Π΅Π»Π΅ΠΆΠ°Π½Π° Π·Π½Π°ΡΠΈΡΠ΅Π»Π½Π° ΡΠ°Π·Π»ΠΈΠΊΠ° Π·Π° p <0.01 ** ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX. ΠΡΠΈ ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° Ξ²2Π Π½Π°ΡΠ³ΠΎΠ»Π΅ΠΌΠΈ ΠΎΡΡΡΠ°ΠΏΡΠ²Π°ΡΠ° ΡΠ΅ Π·Π°Π±Π΅Π»Π΅ΠΆΡΠ²Π°Π°Ρ ΠΊΠ°Ρ ΡΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΊΠΎΠΈ Π±Π΅Π° ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° Π½Π° Piroxicam ΠΈ Ketoprofen, ΠΊΠ°Ρ 91.7% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Ibuprofen, ΠΈ ΠΊΠ°Ρ 50% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Celecoxib. ΠΠΎ, Π²ΠΎ ΡΠ»ΡΡΠ°Ρ Π½Π° ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° (Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ, ΡΡΠΈΠΏΡΠ°Π½ΠΈ ΠΈ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ²ΠΈ) Π΄ΠΎΠΊΠ°ΠΆΠ°Π½ΠΎ Π΅ Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΎ Π·Π³ΠΎΠ»Π΅ΠΌΡΠ²Π°ΡΠ΅ Π½Π° ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΡΠ°.
ΠΠ°ΠΊΠ»ΡΡΠΎΠΊ: Π‘ΠΎ ΡΠΏΠΎΡΡΠ΅Π±Π° Π½Π° NSAID, Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½ΠΈΡΠ΅ ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½ΠΈΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ΅ Π·Π°ΡΠ΅Π³Π½Π°ΡΠΈ Π²ΠΎ ΠΊΡΠ°ΡΠΎΠΊ ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΊΠ°Ρ ΡΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ, ΠΌΠ΅ΡΡΡΠΎΠ° ΡΠ°Π·Π»ΠΈΠΊΠΈΡΠ΅ ΠΏΠΎΠΌΠ΅ΡΡ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈΡΠ΅ Π³ΡΡΠΏΠΈ ΡΠ΅ ΠΌΠ½ΠΎΠ³Ρ ΠΌΠ°Π»ΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΈ. ΠΠΎ ΡΠΏΠΎΡΠ΅Π΄Π±Π° ΡΠΎ ΠΎΠ²ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈ, ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΠΊΠΎΠΈ Π±ΠΈΠ»Π΅ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ°, ΡΠ΅ Π΄Π΅ΡΠ΅ΠΊΡΠΈΡΠ°Π½ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΈ Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½ΠΈ ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½ΠΈ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ°. Π‘Π»Π΅Π΄Π΅ΡΠ΅ΡΠΎ Π½Π° Π½ΠΈΠ²ΠΎΠ°ΡΠ° Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ ΠΌΠΎΠΆΠ΅ΠΌΠ΅ Π΄Π° Π³ΠΎ ΠΊΠΎΡΠΈΡΡΠΈΠΌΠ΅ ΠΊΠ°ΠΊΠΎ ΡΠΈΠ³Π½Π°Π»ΠΈ Π·Π° ΡΠ°Π½ΠΎ ΠΎΡΠΊΡΠΈΠ²Π°ΡΠ΅ Π½Π° Π½Π΅ΡΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡ. ΠΠ°ΠΊΠΎ Π΅ ΠΏΡΠΎΡΠ΅ΡΠΎΡ ΡΠ΅Π²Π΅ΡΠ·ΠΈΠ±ΠΈΠ»Π΅Π½, ΠΌΠΎΠΆΠ΅ΠΌΠ΅ Π΄Π° ΠΏΡΠ΅ΠΏΠΎΡΠ°ΡΠ°ΠΌΠ΅ ΠΏΠΎΡΡΠΎΡΠ°Π½ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ Π½Π° Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΈΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ Π·Π° Π²ΡΠ΅ΠΌΠ΅ Π½Π° Ρ
ΡΠΎΠ½ΠΈΡΠ½Π° ΡΠΏΠΎΡΡΠ΅Π±Π° Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π³ΡΡΠΏΠΈ Π½Π° NSAIDs, ΠΎΡΠΎΠ±Π΅Π½ΠΎ ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΠΊΠ°Π΄Π΅ ΡΡΠΎ Π΅ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎ ΠΏΠΎΡΠ΅Π±Π½ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΏΡΠΈ Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠΈΡΠ°ΡΠ΅ΡΠΎ.
ΠΠ»ΡΡΠ½ΠΈ Π·Π±ΠΎΡΠΎΠ²ΠΈ: AKI, Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ, ΠΌΠΈΠ³ΡΠ΅Π½Π°, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ
ΠΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ Π½Π° ΡΠ΅Π½Π°Π»Π½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ° ΠΊΠ°Ρ Ρ ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ - NSAID
ΠΠ»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠ°ΡΠ° Π΅ Π΅Π΄Π΅Π½ ΠΎΠ΄ Π½Π°ΡΡΠ΅ΡΡΠΈΡΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΠΈ ΡΡΠΎ ΡΠ΅ ΡΡΠ΅ΡΠ°Π²Π° ΠΊΠ°Ρ ΠΎΠΏΡΡΠ°ΡΠ° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡΠ°, ΠΊΠ°ΠΊΠΎ ΠΈ Π²ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°ΡΠ° ΠΏΡΠ°ΠΊΡΠ° Π²ΠΎ ΡΠ΅Π»ΠΈΠΎΡ ΡΠ²Π΅Ρ. Π ΠΏΠΎΠΊΡΠ°Ρ Π²ΠΎΠ²Π΅Π΄ΡΠ²Π°ΡΠ΅ΡΠΎ Π½Π° Π½ΠΎΠ²Π° ΠΊΠ»Π°ΡΠ° Π½Π° ΠΌΠΈΠ³ΡΠ΅Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ ΡΠΎ ΡΡΠΏΠ΅ΡΠΈΠΎΡΠ½Π° Π΅ΡΠΈΠΊΠ°ΡΠ½ΠΎΡΡ ΠΏΡΠ΅Π΄ ΠΏΠΎΠ²Π΅ΡΠ΅ ΠΎΠ΄ Π΅Π΄Π½Π° Π΄Π΅ΡΠ΅Π½ΠΈΡΠ°, ΡΡΠΈΠΏΡΠ°Π½ΠΈ, NSAIDs ΠΎΡΡΠ°Π½ΡΠ²Π°Π°Ρ Π½Π°ΡΡΠ΅ΡΡΠΎ ΠΊΠΎΡΠΈΡΡΠ΅Π½ΠΈΡΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π° Π½Π°ΠΏΠ°Π΄ Π½Π° ΠΌΠΈΠ³ΡΠ΅Π½Π°. ΠΡΡΠΎ ΡΠ°ΠΊΠ°, Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈΡΠ΅ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX (Piroxicam, Ketoprofen, Ibuprofen) ΡΠ΅ Π½Π°ΡΡΠ΅ΡΡΠΎ ΠΏΡΠΎΠΏΠΈΡΠ°Π½ΠΈΡΠ΅ β NSAIDs Π·Π° ΡΡΠ΅ΡΠΌΠ°Π½ Π½Π° Π³Π»Π°Π²ΠΎΠ±ΠΎΠ»ΠΊΠΈ. Celecoxib Π΅ Π΄ΡΡΠ³ Π²ΠΈΠ΄ Π½Π° NSAID, ΠΊΠΎΡΠ° Π΅ ΠΎΠ΄ΠΎΠ±ΡΠ΅Π½Π° Π²ΠΎ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ Π½Π΅ΠΊΠΎΠ»ΠΊΡ Π³ΠΎΠ΄ΠΈΠ½ΠΈ, ΡΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΈ Π½Π° Π΄Π΅ΡΡΡΠ²ΡΠ²Π°ΡΠ΅. ΠΠ΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈΡΠ΅ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ (NSAID)s ΡΠ΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΈ Π΄Π° ΠΏΡΠ΅Π΄ΠΈΠ·Π²ΠΈΠΊΠ°Π°Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π½Π°ΡΡΡΡΠ²Π°ΡΠ° Π½Π° Π±ΡΠ±ΡΠ΅ΠΆΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ°. ΠΠΎΡΡΠ΅Π΄ΡΠ²Π°Π°Ρ ΠΏΡΠ΅ΠΊΡ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΈΡΠ° Π½Π° ΡΠΈΠ½ΡΠ΅Π·Π°ΡΠ° Π½Π° ΠΏΡΠΎΡΡΠ°Π³Π»Π°Π½Π΄ΠΈΠ½ ΡΠΎ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎ Π±Π»ΠΎΠΊΠΈΡΠ°ΡΠ΅ Π½Π° ΡΠΈΠΊΠ»ΠΎΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Π°, ΡΡΠΎ Π΄ΠΎΠ²Π΅Π΄ΡΠ²Π° Π΄ΠΎ Π²Π°Π·ΠΎΠΊΠΎΠ½ΡΡΡΠΈΠΊΡΠΈΡΠ° ΠΈ ΡΠ΅Π²Π΅ΡΠ·ΠΈΠ±ΠΈΠ»Π½ΠΎ Π±Π»Π°Π³ΠΎ Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅ ΠΏΡΠΈ Ρ
ΠΈΠΏΠΎΠΏΠ΅ΡΡΡΠ·ΠΈΡΠ°. ΠΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠ°Π½Π°ΡΠ° ΡΠ°Π½Π° Π΄Π΅ΡΠ΅ΠΊΡΠΈΡΠ° ΠΌΠΎΠΆΠ΅ Π΄Π° Π΄ΠΎΠ²Π΅Π΄Π΅ Π΄ΠΎ Π°ΠΊΡΡΠ½ΠΎ Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅ (AKI). Π‘ΡΠ°Π½Π΄Π°ΡΠ΄Π½ΠΈΡΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈ, ΠΊΠ°ΠΊΠΎ ΡΡΠΎ ΡΠ΅ ΡΠ΅ΡΡΠΌΡΠΊΠΈΡΠ΅ Π½ΠΈΠ²ΠΎΠ° Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ ΠΈ ΡΡΠ΅Π°, ΡΠ΅ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π·Π° ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΠΈΡΠ°ΡΠ° Π½Π° AΠI ΠΈ Π·Π°Π²ΠΈΡΠ°Π°Ρ ΠΎΠ΄ ΡΡΠ΅ΠΏΠ΅Π½ΠΎΡ Π½Π° ΡΠ΅Π½Π°Π»Π½ΠΎΡΠΎ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ΅. ΠΠ°ΡΠΎΠ° Π΅ Π½Π΅ΠΎΠΏΡ
ΠΎΠ΄Π½ΠΎ Π΄Π° ΡΠ΅ ΠΊΠΎΡΠΈΡΡΠ°Ρ ΠΏΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΈ Π·Π° ΡΠ°Π½ΠΎ ΠΎΡΠΊΡΠΈΠ²Π°ΡΠ΅. Π¦Π΅Π»ΡΠ° Π½Π° ΡΡΡΠ΄ΠΈΡΠ°ΡΠ° Π΅ Π΄Π° ΡΠ΅ ΡΠ»Π΅Π΄ΠΈ Π±ΡΠ±ΡΠ΅ΠΆΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ° ΠΊΠ°Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ½ΠΎ ΡΡΠ΅ΡΠΈΡΠ°ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅ΡΠ°Π»Π΅Π°-ΠΌΠΈΠ³ΡΠ΅Π½Π°.
ΠΠΏΠΈΡ Π½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΠ°ΡΠ° β ΠΠΎΡΠΈΡΡΠ΅Π½Π° Π΅ JaffΠ΅-ΠΎΠ²Π°ΡΠ° ΠΌΠ΅ΡΠΎΠ΄Π° Π·Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ²Π°ΡΠ΅ Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ Π²ΠΎ ΡΠ΅ΡΡΠΌ/ΡΡΠΈΠ½Π° ΠΈ Π΅Π½Π·ΠΈΠΌΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ Π·Π° ΡΡΠ΅Π° ΠΈ ΠΌΠΎΠΊΡΠ°ΡΠ½Π° ΠΊΠΈΡΠ΅Π»ΠΈΠ½Π° Π²ΠΎ ΡΠ΅ΡΡΠΌ ΠΈ ᡧ-glutamyl transferase (ᡧ-GT) Π²ΠΎ ΡΡΠΈΠ½Π° / ΡΠ΅ΡΡΠΌ. ΠΡΠ·ΠΈΠ½Π°ΡΠ° Π½Π° Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½Π°ΡΠ° ΡΠΈΠ»ΡΡΠ°ΡΠΈΡΠ° - Glomerular filtration rate (GFR) Π΅ ΠΏΡΠ΅ΡΠΌΠ΅ΡΠ°Π½Π° ΡΠΎ ΠΏΠΎΠΌΠΎΡ Π½Π° Cockcroft Gaunt ΡΠΎΡΠΌΡΠ»Π°ΡΠ° ΠΈ ΠΠΎΠ½-ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ Π΅Π»Π΅ΠΊΡΡΠΎΠ΄ΠΈ -(ISE) Π·Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ²Π°ΡΠ΅ Π½Π° Π΅Π»Π΅ΠΊΡΡΠΎΠ»ΠΈΡΠΈΡΠ΅ Π²ΠΎ ΡΠ΅ΡΡΠΌΠΎΡ. ΠΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ ΡΠ΅ ΠΊΠΎΡΠΈΡΡΠ΅Π½ΠΈ Π·Π° ΠΎΠ΄ΡΠ΅Π΄ΡΠ²Π°ΡΠ΅ Π½Π° N-Π°ΡΠ΅ΡΠΈΠ»βΞ²-D--Π³Π»ΡΠΊΠΎΠ·Π°ΠΌΠΈΠ΄Π°Π·Π° (NAG) ΠΈ ΠΠ»Π°Π½ΠΈΠ½ Π°ΠΌΠΈΠ½ΠΎΠΏΠ΅ΠΏΡΠΈΠ΄Π°Π·Π° (AAP). ΠΠΌΡΠ½ΠΎΡΡΡΠ±ΠΎΠ΄ΠΈΠΌΠ΅ΡΡΠΈΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈ, Π½Π΅ΡΠ΅Π»ΠΎΠΌΠ΅ΡΡΠΈΡΠ° ΠΈ ΡΠΎΡΠΎΠ΅Π»Π΅ΠΊΡΡΠΈΡΠ½a ΠΊΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ° ΡΠ΅ ΡΠΏΠΎΡΡΠ΅Π±Π΅Π½ΠΈ Π·Π° ΠΎΠ΄ΡΠ΅Π΄ΡΠ²Π°ΡΠ΅ Π½Π° ΡΡΠΈΠ½Π°ΡΠ½ΠΈΡΠ΅ Π°Π»Π±ΡΠΌΠΈΠ½ΠΈ, ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΠ°ΡΠ°, Ξ±1-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΡ (Ξ±1M) ΠΈ Ξ²2-ΠΌΠΈΠΊΡΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ (Ξ²2Π) Π·Π° Π΄Π° ΡΠ΅ ΡΠ»Π΅Π΄ΠΈ Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½Π°ΡΠ° ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½Π°ΡΠ° ΡΡΠ½ΠΊΡΠΈΡΠ°. Π’Π΅ΡΡΠΈΡΠ°Π²ΠΌΠ΅ 136 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ΅ΡΠ°Π»Π΅Π° ΠΌΠΈΠ³ΡΠ΅Π½Π° ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ Π΄ΠΎΠ»Π³ΠΈ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈ Π½Π° 10, 5 ΠΈ 1 Π³ΠΎΠ΄ΠΈΠ½a ΡΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ NSAIDs Π·Π°ΡΠ½ΠΎΠ²Π°Π½ΠΈ Π½Π° ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΈΡΠ° Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ (Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ, Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ²Π½ΠΈ ΠΈ ΡΡΠΈΠΏΡΠ°Π½ΠΈ). ΠΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΠ΅ ΡΠΏΠΎΡΠ΅Π΄Π΅Π½ΠΈ ΡΠΎ 80 ΠΈΡΠΏΠΈΡΠ°Π½ΠΈΡΠΈ ΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° Π³ΡΡΠΏΠ° (ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π²ΠΎ ΠΎΠ΄Π½ΠΎΡ Π½Π° ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΡ), Π° Π½Π΅ΠΊΠΎΠΈ Π³ΡΡΠΏΠΈ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎ Π΅Π΄Π΅Π½ ΠΌΠ΅ΡΠ΅Ρ ΠΏΠ°ΡΠ·Π° Π±Π΅Π· Π½ΠΈΠΊΠ°ΠΊΠ²Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎ ΡΠ΅ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠ°Π½ΠΈ.
Π Π΅Π·ΡΠ»ΡΠ°ΡΠΈ: ΠΠΎΠ½ΡΡΠ°ΡΠΈΡΠ°Π½ΠΎ Π΅ Π΄Π΅ΠΊΠ° Π½Π΅ΠΌΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈ Π·Π½Π°ΡΠ°ΡΠ½ΠΈ ΠΏΡΠΎΠΌΠ΅Π½ΠΈ Π²ΠΎ Π²ΡΠ΅Π΄Π½ΠΎΡΡΠΈΡΠ΅ Π½Π° ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½ΠΎΡ (ΡΡΠΈΠ½Π°/ΡΠ΅ΡΡΠΌ), ΡΡΠ΅Π°ΡΠ°, Π΅Π»Π΅ΠΊΡΡΠΎΠ»ΠΈΡΠΈΡΠ΅ Π²ΠΎ ΡΠ΅ΡΡΠΌΠΎΡ ΠΈ GFR. ΠΠΎ ΠΎΠ΄Π½ΠΎΡ Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ Π½Π° ΡΡΠΈΠ½Π°ΡΠ° (NAG, AAP, ᡧ-GT, ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΡΠ° ΠΈ Ξ± 1 M), ΡΡΠ²ΡΠ΄Π΅Π½ΠΈ ΡΠ΅ ΡΠΈΠ³Π½ΠΈΡΠΈΠΊΠ°Π½ΡΠ½ΠΈ Π·Π³ΠΎΠ»Π΅ΠΌΡΠ²Π°ΡΠ° Π½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡΠΈΡΠ΅ ΠΊΠ°Ρ ΡΠΈΡΠ΅ Π³ΡΡΠΏΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ NSAIDs ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Caffetin+NSAID Π²ΠΎ ΡΠΏΠΎΡΠ΅Π΄Π±Π° ΡΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° Π³ΡΡΠΏΠ° Π½Π° ΠΈΡΠΏΠΈΡΠ°Π½ΠΈΡΠΈ, Π° ΡΠΎΡΡΠΎΡΠ±Π°ΡΠ° ΡΠ΅ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΈΡΠ° ΠΏΠΎ ΠΏΠ°ΡΠ·Π° ΠΎΠ΄ Π΅Π΄Π΅Π½ ΠΌΠ΅ΡΠ΅Ρ Π±Π΅Π· Π½ΠΈΠΊΠ°ΠΊΠ²Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ°. ΠΡΠΈ ΡΡΠ΅ΡΠΌΠ°Π½ Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° Π½Π° COX (Piroxicam, Ketoprofen, Ibuprofen), ΡΠ΅Π»Π°ΡΠΈΠ²Π½ΠΎ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ COX2 ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ (Nimesulid/Meloxicam) ΠΈ ΡΠΎ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX2 (Celecoxib) ΠΏΡΠΈ ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΠΎΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅Ρ (ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΠ°) Π΅ Π·Π°Π±Π΅Π»Π΅ΠΆΠ°Π½Π° Π·Π½Π°ΡΠΈΡΠ΅Π»Π½Π° ΡΠ°Π·Π»ΠΈΠΊΠ° Π·Π° p <0.01 ** ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX. ΠΡΠΈ ΡΠ»Π΅Π΄Π΅ΡΠ΅ Π½Π° Ξ²2Π Π½Π°ΡΠ³ΠΎΠ»Π΅ΠΌΠΈ ΠΎΡΡΡΠ°ΠΏΡΠ²Π°ΡΠ° ΡΠ΅ Π·Π°Π±Π΅Π»Π΅ΠΆΡΠ²Π°Π°Ρ ΠΊΠ°Ρ ΡΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΊΠΎΠΈ Π±Π΅Π° ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° Π½Π° Piroxicam ΠΈ Ketoprofen, ΠΊΠ°Ρ 91.7% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Ibuprofen, ΠΈ ΠΊΠ°Ρ 50% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΠΏΠΎΠ΄ ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΡΠΎ Celecoxib. ΠΠΎ, Π²ΠΎ ΡΠ»ΡΡΠ°Ρ Π½Π° ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° (Π°Π½Π°Π»Π³Π΅ΡΠΈΡΠΈ, ΡΡΠΈΠΏΡΠ°Π½ΠΈ ΠΈ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΠΈΠ²ΠΈ) Π΄ΠΎΠΊΠ°ΠΆΠ°Π½ΠΎ Π΅ Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΎ Π·Π³ΠΎΠ»Π΅ΠΌΡΠ²Π°ΡΠ΅ Π½Π° ΠΌΠΈΠΊΡΠΎΠ°Π»Π±ΡΠΌΠΈΠ½ΡΡΠΈΡΠ°.
ΠΠ°ΠΊΠ»ΡΡΠΎΠΊ: Π‘ΠΎ ΡΠΏΠΎΡΡΠ΅Π±Π° Π½Π° NSAID, Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½ΠΈΡΠ΅ ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½ΠΈΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ΅ Π·Π°ΡΠ΅Π³Π½Π°ΡΠΈ Π²ΠΎ ΠΊΡΠ°ΡΠΎΠΊ ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΊΠ°Ρ ΡΠΈΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ, ΠΌΠ΅ΡΡΡΠΎΠ° ΡΠ°Π·Π»ΠΈΠΊΠΈΡΠ΅ ΠΏΠΎΠΌΠ΅ΡΡ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈΡΠ΅ Π³ΡΡΠΏΠΈ ΡΠ΅ ΠΌΠ½ΠΎΠ³Ρ ΠΌΠ°Π»ΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΈ. ΠΠΎ ΡΠΏΠΎΡΠ΅Π΄Π±Π° ΡΠΎ ΠΎΠ²ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈ, ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈΡΠ΅ ΠΊΠΎΠΈ Π±ΠΈΠ»Π΅ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ°, ΡΠ΅ Π΄Π΅ΡΠ΅ΠΊΡΠΈΡΠ°Π½ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΈ Π³Π»ΠΎΠΌΠ΅ΡΡΠ»Π°ΡΠ½ΠΈ ΠΈ ΡΡΠ±ΡΠ»Π°ΡΠ½ΠΈ ΠΎΡΡΠ΅ΡΡΠ²Π°ΡΠ°. Π‘Π»Π΅Π΄Π΅ΡΠ΅ΡΠΎ Π½Π° Π½ΠΈΠ²ΠΎΠ°ΡΠ° Π½Π° ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈΡΠ΅ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ ΠΌΠΎΠΆΠ΅ΠΌΠ΅ Π΄Π° Π³ΠΎ ΠΊΠΎΡΠΈΡΡΠΈΠΌΠ΅ ΠΊΠ°ΠΊΠΎ ΡΠΈΠ³Π½Π°Π»ΠΈ Π·Π° ΡΠ°Π½ΠΎ ΠΎΡΠΊΡΠΈΠ²Π°ΡΠ΅ Π½Π° Π½Π΅ΡΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡ. ΠΠ°ΠΊΠΎ Π΅ ΠΏΡΠΎΡΠ΅ΡΠΎΡ ΡΠ΅Π²Π΅ΡΠ·ΠΈΠ±ΠΈΠ»Π΅Π½, ΠΌΠΎΠΆΠ΅ΠΌΠ΅ Π΄Π° ΠΏΡΠ΅ΠΏΠΎΡΠ°ΡΠ°ΠΌΠ΅ ΠΏΠΎΡΡΠΎΡΠ°Π½ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ Π½Π° Π±ΡΠ±ΡΠ΅ΠΆΠ½ΠΈΡΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ Π·Π° Π²ΡΠ΅ΠΌΠ΅ Π½Π° Ρ
ΡΠΎΠ½ΠΈΡΠ½Π° ΡΠΏΠΎΡΡΠ΅Π±Π° Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π³ΡΡΠΏΠΈ Π½Π° NSAIDs, ΠΎΡΠΎΠ±Π΅Π½ΠΎ ΠΊΠ°Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΡΠ΅ΡΠΈΡΠ°Π½ΠΈ ΡΠΎ Π½Π΅ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΈ ΠΈΠ½Ρ
ΠΈΠ±ΠΈΡΠΎΡΠΈ Π½Π° COX ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠ°Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° ΠΊΠ°Π΄Π΅ ΡΡΠΎ Π΅ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎ ΠΏΠΎΡΠ΅Π±Π½ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΏΡΠΈ Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠΈΡΠ°ΡΠ΅ΡΠΎ.
ΠΠ»ΡΡΠ½ΠΈ Π·Π±ΠΎΡΠΎΠ²ΠΈ: AKI, Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΠΈ Π°Π½ΡΠΈΠΈΠ½ΡΠ»Π°ΠΌΠ°ΡΠΎΡΠ½ΠΈ Π»Π΅ΠΊΠΎΠ²ΠΈ, ΠΌΠΈΠ³ΡΠ΅Π½Π°, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ
Evaluation a renal function of patients with Medication-overuse headache (MOH)
Excessive drug use causes Medication-overuse headache (MOH) which can be manifested with chronic daily headaches, occurring monthly 15 or more days when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug-induced disorders suggest that an increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MOH), who were treated with NSAIDs in combination with other drugs (analgesics, triptans, and antidepressants) and compared patients treated only with Diclofenac, Piroxicam, Ketoprofen, Paracetamol, Ibuprofen, and Celecoxib. Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum). Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria, and Ξ²2-microglobulin will be used. Significant glomerular and tubular damage has been reported, and patients on combination therapy with NSAIDs and other drugs (analgesics, triptans, and antidepressants) have seen more glomerular changes than patients treated with NSAID monotherapy
Monitoring of the renal function in Indometacin treated patients with rheumatoid arthritis
Abstract Nonsteroidal antiinflamatory drugs (NSAIDs) are considered as one of the most nephrotoxic drugs and their use in chronic rheumatic treatment is frequently accompanied by renal impairments of various pathophysiology and severity. The aim of this study was to evaluate the kidney performance among Indometacin treated patients with rheumatoid arthritis (RA). A total of 20 patients (14-RAsero+,6-RAsero-) with an average age of 46,57 Β±7,51,suffering from chronic rheumatic pain were evaluated quarterly for one year and once more one month after discontinuation of treatment. The results were compared to the reference interval and a control group of 80 healthy individuals. A panel of 5 urinary specific nephrotoxicity biomarkers including N-Acetyl-Ξ²-(D)-GlucosaminidaseΒ (NAG), Alanine Aminopeptidase (AAP), Ξ³-glutamyl transferase (Ξ³βGT),Ξ±1 Microgloglobulin (Ξ±1M) and microalbuminuria,was used to monitor glomerular and tubular functioning. Present or past history of kidney disease was considered an exclusion criteria for enrollment in the study. After a 12 month treatment with Indometacin (2x25mg) a significant increase of the evaluated markers was evident among all patients, except for microalbuminuria and Ξ±1M which were insignificantly increased among RAsero- patients and did not exit the reference interval. These findings suggest a renal impairment resulting from Indometacin nephrotoxicity but might also be affected by the rheumatic complications. Fortunately, the damage is reversible at this stage and the evaluated parameters normalize within one month after the cessation of treatment indicating that the detected impairment is predominantly caused by the toxicity of Indometacin. Further studies are needed to precisely differentiate the level of impairment caused by the NSAIDs and the rheumatic pathology itself but we strongly recommend regular monitoring of the renal performance in patients undergoing continuous Indometacin treatment for rheumatic pain. Keywords: Biomarkers, Nephrotoxicity, Nonsteroidal antiinflamatory drugs, rheumatoid arthritis.